Idoka (Sildenafil)

Sildenafil is a phosphodiesterase type 5 inhibitor used in conditions related to vascular smooth‑muscle tone.

• Erectile dysfunction: improves the ability to achieve and maintain an erection in men with this condition.
• Pulmonary arterial hypertension: lowers pulmonary arterial pressure and enhances exercise capacity.
• No other approved therapeutic indications: the drug is not authorized for additional conditions.

• Sildenafil selectively inhibits the enzyme phosphodiesterase type 5, preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels lead to relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature, facilitating increased blood flow and improved erectile function or reduced pulmonary arterial pressure.

Sildenafil may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warmth and redness of the face or upper body.
• Dyspepsia: indigestion or upset stomach.
• Nasal congestion: stuffy or runny nose.
• Visual disturbances: blurred vision or color tinge.
• Back pain: muscle aches, often in the lower back.

Serious or Rare Side Effects

• Priapism: prolonged erection lasting more than four hours.
• Sudden vision loss: abrupt loss of vision in one or both eyes.
• Sudden hearing loss: unexplained loss of hearing.
• Severe hypotension: marked drop in blood pressure.
• Myocardial infarction: rare heart attack events.

Before prescribing Idoka, clinicians should consider several safety factors.

• Assess cardiovascular status: ensure the patient can safely engage in sexual activity.
• Review nitrate therapy: concomitant use with nitrates is contraindicated.
• Evaluate liver and kidney function: dose adjustments may be required in impairment.
• Avoid use in severe hypotension: patients with low blood pressure are at increased risk.
• Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Sildenafil can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin): may cause severe hypotension.
• Nitric oxide donors (e.g., riociguat): risk of dangerous blood pressure drop.

Moderate Interactions (Monitor Closely)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce sildenafil effectiveness.
• Alpha‑blockers (e.g., doxazosin): may cause additive blood pressure lowering.
• Antihypertensive agents: monitor for excessive hypotension.